Amneal Pharmaceuticals (NYSE:AMRX) announces the FDA nod for its generic version of Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg.
The antipsychotic med was originally marketed under the brand name Prolixin by Bristol-Myers Squibb for the treatment of schizophrenia, since discontinued.
Commercial launch is underway.
Per IQVIA, the U.S. market is ~$143M.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.